Cardiac allograft vasculopathy: a review
- PMID: 9323100
- DOI: 10.1161/01.cir.96.6.2069
Cardiac allograft vasculopathy: a review
Abstract
Cardiac allograft vasculopathy (CAV) remains a troublesome long-term complication of heart transplantation. It is manifested by a unique and unusually accelerated form of coronary disease affecting both intramural and epicardial coronary arteries and veins.CAV is characterized by vascular injury induced by a variety of noxious stimuli, including the immune system response to the allograft, ischemia-reperfusion injury, viral infection, immunosuppressive drugs, and classic risk factors such as hyperlipidemia, insulin resistance, and hypertension. The obstructive vascular lesions are thought to progress through repetitive endothelial injury followed by repair response. The role of major histocompatibility complex donor-recipient differences in the pathogenesis of CAV has not yet been completely elucidated. Intracoronary ultrasound studies reveal a dual morphology with donor-transmitted or de novo focal, noncircumferential plaques in proximal segments and/or a diffuse, concentric pattern observed in distal segments. A lack of correlation between microvascular and epicardial vessel disease suggests discordant manifestations and progression of CAV. Apoptosis and loss of functional vascular remodeling have to be considered as important mediators of clinically relevant CAV. Strategies for blocking T-cell costimulation and expression of adhesion molecules may help prevent chronic rejection in clinical transplantation. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and antiproliferative drugs may slow progression of CAV by various effects. Methods to augment endogenous nitric oxide bioavailability as well as newer immunosuppressive regimens may be protective. Balloon angioplasty has a limited role in the treatment of focal lesions. Experiences with coronary stenting, coronary artery bypass grafting, and transmyocardial laser revascularization are limited. Retransplantation has a worse outcome than initial transplantation.
Similar articles
-
The continuing challenge of cardiac transplant arteriosclerosis.Cardiologia. 1998 Aug;43(8):777-87. Cardiologia. 1998. PMID: 9808867 Review.
-
Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium.Circulation. 1995 Jul 15;92(2):205-11. doi: 10.1161/01.cir.92.2.205. Circulation. 1995. PMID: 7600652
-
Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death.Circulation. 2001 Dec 18;104(25):3091-6. doi: 10.1161/hc5001.100796. Circulation. 2001. PMID: 11748106 Clinical Trial.
-
Coronary artery disease in the transplanted heart.Annu Rev Med. 2000;51:81-100. doi: 10.1146/annurev.med.51.1.81. Annu Rev Med. 2000. PMID: 10774454 Review.
-
Pathogenetic mechanisms of cardiac allograft vasculopathy--impact of nitric oxide.Z Kardiol. 2000;89 Suppl 9:IX/24-7. doi: 10.1007/s003920070022. Z Kardiol. 2000. PMID: 11151787
Cited by
-
Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY).Transpl Int. 2024 Apr 5;37:11878. doi: 10.3389/ti.2024.11878. eCollection 2024. Transpl Int. 2024. PMID: 38644935 Free PMC article.
-
Acute myocardial infarction in heart transplant recipients: An 18-year national study.Am Heart J Plus. 2022 Jun 30;17:100167. doi: 10.1016/j.ahjo.2022.100167. eCollection 2022 May. Am Heart J Plus. 2022. PMID: 38559875 Free PMC article.
-
Protein Phosphatase 2A Activation Promotes Heart Transplant Acceptance in Mice.Transplantation. 2024 Mar 1;108(3):e36-e48. doi: 10.1097/TP.0000000000004832. Epub 2023 Oct 17. Transplantation. 2024. PMID: 38126420
-
Cardiac macrophage metabolism in health and disease.Trends Endocrinol Metab. 2024 Mar;35(3):249-262. doi: 10.1016/j.tem.2023.10.011. Epub 2023 Nov 21. Trends Endocrinol Metab. 2024. PMID: 37993313 Review.
-
Accelerated Cardiac Allograft Vasculopathy in an Orthotopic Heart Transplant Recipient with Prior COVID-19.Am J Case Rep. 2023 Mar 1;24:e937955. doi: 10.12659/AJCR.937955. Am J Case Rep. 2023. PMID: 36855283 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical